Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heart

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 18-26

  Schneider, Jay W ^a,d   Chang, Alice Y ^a,b,c   Rocco, Thomas P ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Cardiovascular Division and the Division of General Internal Medicine   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; NEU DIFFERENTIATION FACTOR; PACLITAXEL; PROTEIN TYROSINE KINASE; RECEPTOR ANTIBODY; TRASTUZUMAB;

BREAST CANCER; CANCER CELL; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL GROWTH; CELL REGENERATION; CELL SURVIVAL; CONFERENCE PAPER; CONTROLLED STUDY; HEART DEVELOPMENT; HEART MUSCLE CELL; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035160313     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28546     Document Type: Conference Paper

References (24)

1. An overview of monoclonal antibody therapy of cancer
2. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
3. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
4. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
5. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
6. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
7. Basic science of HER-2/neu: A review
8. Principles of receptor-based inhibition of erbB family receptor kinases: Prospects for new therapies for human cancers
9. Congestive heart failure: Fifty years of progress
10. Asymptomatic left ventricular dysfunction in the community
11. Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study
12. Signaling pathways in cardiac myocyte hypertrophy
13. Cardiotoxicity of chemotherapeutic agents: Incidence, treatment and prevention
14. Involvement of phosphorylation in doxorubicin-mediated myofibril degeneration: An immunofluorescence microscopy analysis
15. Complexity in simplicity: Monogenic disorders and complex cardiomyopathies
16. Cardiotoxicity in patients receiving trastuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
17. Requirement for neuregulin receptor erbB2 in neural and cardiac development
18. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases
19. Aberrant neural and cardiac development in mice lacking the ErbB 4 neuregulin receptor
20. Neuregulins promote survival and growth of cardiac myocytes: Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes
21. Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors
22. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active
23. Trastuzumab in the treatment of metastatic breast cancer: Anticancer therapy versus cardiotoxicity